Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma

NCT00422019 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00422019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00422019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
March 31, 2009
Enrollment
61 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma